These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10400373)

  • 1. Chronic myelogenous leukemia.
    Osarogiagbon UR; McGlave PB
    Curr Opin Hematol; 1999 Jul; 6(4):241-6. PubMed ID: 10400373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myelogenous leukemia.
    Mauro MJ; Druker BJ
    Curr Opin Oncol; 2001 Jan; 13(1):3-7. PubMed ID: 11148678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advancements in the treatment of chronic myelogenous leukemia.
    O'Dwyer ME; Mauro MJ; Druker BJ
    Annu Rev Med; 2002; 53():369-81. PubMed ID: 11818480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model mice for BCR/ABL-positive leukemias.
    Honda H; Hirai H
    Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
    Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
    Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current therapy of chronic myelogenous leukemia.
    Garcia-Manero G; Talpaz M; Kantarjian HM
    Intern Med; 2002 Apr; 41(4):254-64. PubMed ID: 11993784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Munthe HA; Verfaillie CM
    Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloid leukemia stem cells.
    Jamieson CH
    Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
    Drexler HG; MacLeod RA; Uphoff CC
    Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allo-SCT in a rare t(8;21) evolution of CML.
    Hsiao HH; Tsai HJ; Liu YC; Lee CP; Lin SF
    Bone Marrow Transplant; 2010 Aug; 45(8):1365-6. PubMed ID: 20023710
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic myelogenous leukemia: biology and therapy.
    Gale RP; Grosveld G; Canaani E; Goldman JM
    Leukemia; 1993 Apr; 7(4):653-8. PubMed ID: 8464245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?
    Verfaillie CM; Hurley R; Lundell BI; Zhao C; Bhatia R
    Acta Haematol; 1997; 97(1-2):40-52. PubMed ID: 8980609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment.
    Clarkson B; Strife A
    Leukemia; 1993 Nov; 7(11):1683-721. PubMed ID: 8231240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When to Consider Allogeneic Transplantation in CML.
    Radich J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S93-5. PubMed ID: 27521333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
    Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
    Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biology and treatment of chronic myelogenous leukemia.
    Giles FJ; Kantarjian HM
    Oncology (Williston Park); 1997 Sep; 11(9):1295-300; discussion 1302-10. PubMed ID: 9306419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.